Ticagrelor monotherapy after short duration of dual antiplatelet therapy compared to continued dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary interventions: an updated meta-analysis

被引:0
|
作者
Mansuri, Zeeshan [1 ]
Ashraf, Hadiah [2 ]
Taikadan, Thahsin [3 ]
Rajith, Gokul [4 ]
Ayesha, Ayesha [5 ]
Fatima, Urooj [6 ]
Erzinger, Gabriel [7 ]
机构
[1] GCS Med Coll & Res Ctr, Dept Cardiol, Opp DRM Off,Naroda Rd, Ahmadabad 380025, Gujarat, India
[2] Rawalpindi Med Univ, Rawalpindi, Pakistan
[3] Calicut Med Coll, Kozhikode, India
[4] All India Inst Med Sci, Gauhati, India
[5] Shifa Coll Med, Islamabad, Pakistan
[6] Jinnah Sindh Med Univ, Karachi, Pakistan
[7] Univ Joinville Reg UNIVILLE, Joinville, Brazil
关键词
dual anti-platelet therapy; percutaneous coronary intervention; ticagrelor; ASPIRIN;
D O I
10.1097/MCA.0000000000001417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The optimum duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes (ACS) remains controversial. Ticagrelor monotherapy after short duration of DAPT (1-3 months) is a subject of research. We conducted an updated systematic review and meta-analysis comparing the ticagrelor monotherapy with continued DAPT after short duration of DAPT in patients with ACS undergoing PCI. Methods PubMed, Embase, and Cochrane databases were searched for studies comparing ticagrelor monotherapy to DAPT after PCI and reported the outcomes of major adverse cardiovascular and cerebrovascular events (MACCE); net adverse clinical events (NACE); myocardial infarction (MI); major bleeding; death from any cause; definite or probable stent thrombosis; and target vessel revascularization (TVR). Data were extracted from published reports and quality assessment was performed per Cochrane recommendations. Statistical analysis was performed using Review Manager (Cochrane collaboration). Heterogeneity was examined with I-2 test. Results Of 3,208 results, five studies with 21,407 patients were included of which 50% received ticagrelor monotherapy. Studies had reported follow up of 12 months. Major bleeding [hazard ratio 0.47; 95% confidence interval (CI), 0.37-0.61; P < 0.001], NACE (hazard ratio 0.71; 95% CI, 0.56-0.90; P = 0.005), and all-cause death (hazard ratio 0.76; 95% CI, 0.59-0.98; P = 0.04) were significantly less with ticagrelor monotherapy. Other outcomes were comparable in both groups. Conclusion In patients with ACS undergoing PCI, ticagrelor monotherapy reduces major bleeding, NACE and all-cause death as compared to continued DAPT for 12 months. Major ischemic outcomes were similar. Ticagrelor monotherapy is the way forward after short duration of DAPT after PCI in ACS.
引用
收藏
页码:590 / 597
页数:8
相关论文
共 50 条
  • [31] SHORT DURATION OF DUAL ANTIPLATELET THERAPY FOLLOWING COMPLEX PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Takla, Andrew
    Eid, Mohamed
    Zaalouk, Mostafa
    Mohamed, Sarah
    Goldsweig, Andrew Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1073 - 1073
  • [32] Short duration of dual antiplatelet therapy following complex percutaneous coronary intervention: A systematic review and meta-analysis
    Eid, Mohamed Magdi
    Mostafa, Mostafa Reda
    Alabdouh, Ahmad
    Najim, Mostafa
    Mohamed, Sarah
    Ziada, Abdul Rahman
    Takla, Andrew
    Balmer-Swain, Mallory
    Baibhav, Bipul
    Al-Azizi, Karim M.
    Goldsweig, Andrew M.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2024, 61 : 8 - 15
  • [33] Effectiveness and Safety of Ticagrelor Monotherapy After Short-Duration Dual Antiplatelet Therapy in PCI Patients: A Systematic Review and Meta-Analysis
    Alagna, Giulia
    Trimarchi, Giancarlo
    Cascone, Alessia
    Villari, Alessio
    Cavolina, Giulia
    Campanella, Francesca
    Micari, Antonino
    Taverna, Giovanni
    Ando, Giuseppe
    AMERICAN JOURNAL OF CARDIOLOGY, 2025, 241 : 69 - 74
  • [34] Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
    Bainey, Kevin R.
    Marquis-Gravel, Guillaume
    Macdonald, Blair J.
    Bewick, David
    Yan, Andrew
    Turgeon, Ricky D.
    PLOS ONE, 2023, 18 (09):
  • [35] Extended Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Peripheral Arterial Disease: A Meta-Analysis
    Ling, Hua
    Andrews, Ebony
    Ombengi, David
    Li, Fang
    CARDIOLOGY RESEARCH, 2018, 9 (03) : 137 - 143
  • [36] Extended duration dual antiplatelet therapy after percutaneous coronary intervention in patients with peripheral arterial disease: a meta-analysis
    Ling, Hua
    Andrews, Ebony
    Ombengi, David
    Brown, Danielle
    PHARMACOTHERAPY, 2017, 37 (12): : E234 - E234
  • [37] Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis
    Wang, Xin
    Wang, Shihui
    Yang, Jing
    Yu, Xiaojia
    Liu, Lihong
    THROMBOSIS RESEARCH, 2020, 193 : 130 - 138
  • [38] Duration of dual antiplatelet therapy in acute coronary syndrome
    Wilson, Simon John
    Newby, David E.
    Dawson, Dana
    Irving, John
    Berry, Colin
    HEART, 2017, 103 (08) : 573 - 580
  • [39] Clopidogrel Versus Ticagrelor as Part of Dual-Antiplatelet Therapy for Patients With Acute Coronary Syndrome: A Meta-Analysis
    Myredal, Anna
    Bergh, Niklas
    Sjovall, Henrik
    Wallerstedt, Susanna
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (19) : B193 - B193
  • [40] Ischemic Versus Bleeding Risk Consideration for the Duration of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Interventions
    Gajanana, Deepakraj
    Rogers, Toby
    Iantorno, Micaela
    Weintraub, William
    Shlofmitz, Evan
    Khalid, Nauman
    Chen, Yuefeng
    Torguson, Rebecca
    Khan, Jaffar
    Musallam, Anees
    Ben-Dor, Itsik
    Satler, Lowell
    Waksman, Ron
    JACC-CARDIOVASCULAR INTERVENTIONS, 2019, 12 (04) : S10 - S11